WYE-120318, a ring contraction product of methylnaltrexone, and structure revision of coniothyrione

Magn Reson Chem. 2012 Dec;50(12):829-33. doi: 10.1002/mrc.3892. Epub 2012 Nov 8.

Abstract

A contracted ring degradation product, WYE-120318 (compound 2), was discovered during the development phase for methylnaltrexone bromide (compound 1) drug substance. The compound was isolated by high-performance liquid chromatography fractionation, and its structure was determined by spectroscopic data analyses. WYE-120318 is formed from methylnaltrexone through a benzyl-benzilic acid type rearrangement reaction to yield an α-hydroxy-cyclopentanecarboxylic acid substructure. The proposed structure and the formation mechanism are confirmed by the synthesis of WYE-120318 from methylnaltrexone (compound 1). A similar benzyl-benzilic acid type rearrangement reaction can be envisioned as the biological origin of remisporine A (compound 3), a naturally occurring cyclopentadienyl compound that autocatalytically dimerizes to remisporine B (compound 4). The structure of remisporine A was deduced from its dimer 4. Coniothyione (compound 5) can be considered as the first example of a stable natural product bearing the remisporine A skeleton. However, the regiochemistry of the chlorosubstitution in the coniothyrione structure needs to be revised to compound 6 on the basis of the nuclear magnetic resonance data and biogenesis analysis.

MeSH terms

  • Catalysis
  • Chromatography, High Pressure Liquid
  • Chromones / chemistry*
  • Dimerization
  • Magnetic Resonance Spectroscopy
  • Naltrexone / analogs & derivatives*
  • Naltrexone / chemical synthesis
  • Naltrexone / chemistry
  • Quaternary Ammonium Compounds / chemistry
  • Stereoisomerism

Substances

  • Chromones
  • Quaternary Ammonium Compounds
  • WYE-120318
  • coniothyrione
  • methylnaltrexone
  • Naltrexone